雷贝拉唑与艾司奥美拉唑钠治疗幽门螺杆菌感染疗效及安全性比较  

Comparison of efficacy and security of rabeprazole and esomeprazole in the treatment of helicobacter pylori infection

作　　者：张鑫赫 曾子露 王雪[1] 陈莫耶[1] 田昊宇 李异玲[1] ZHANG Xin-he;ZENG Zi-lu;WANG Xue;CHEN Mo-ye;TIAN Hao-yu;LI Yi-ling(Department of Gastroenterology,the First Hospital of China Medical University,Shenyang 110001,China;不详)

机构地区：[1]中国医科大学附属第一医院消化内科,辽宁沈阳110001 [2]中国医科大学,辽宁沈阳110122

出　　处：《中国实用内科杂志》2021年第10期885-889,共5页Chinese Journal of Practical Internal Medicine

基　　金：辽宁省自然基金指导计划(20180550049)。

摘　　要：目的比较雷贝拉唑钠肠溶胶囊和艾司奥美拉唑钠肠溶片在辽宁地区治疗幽门螺杆菌感染的疗效和安全性。方法选取2017年3月至2019年10月符合条件的212例幽门螺杆菌阳性的患者,随机分成RBCA组(106例)和EBCA组(106例),RBCA组实施:雷贝拉唑钠肠溶胶囊、胶体果胶铋胶囊、克拉霉素片、阿莫西林,EBCA组实施:艾司奥美拉唑钠肠溶片、胶体果胶铋胶囊、克拉霉素片、阿莫西林。两组均治疗14 d,停药4周后进行^(13)C呼气试验复查比较2组根除率及不良反应率。结果RBCA组根除率为87.13%,不良反应率为12.87%,EBCA组根除率为85.58%,不良反应率为19.23%,2组的根除率及不良反应率差异均无统计学意义。结论雷贝拉唑和艾司奥美拉唑钠对辽宁地区幽门螺杆菌感染患者的疗效和安全性无差异。Objective To compare the efficacy and security of rabeprazole and esomeprazole in the treatment of helicobacter pylori infection in Liaonig Province.Methods 212 elidible HP-positive patients in the First Hospital of China Medical University were choosed form March 2017 to October 2019,who were divided into group RBCA(160 cases)and group EBCA(160 cases).Group RBCA:rabeprazole,bismuth,clarithromycin,amoxicillin.Group EBCA:esomeprazole,bismuth,clarithromycin,amoxicillin.The patients in both groups were treated for 14 days.And then they were rechecked by^(13)C breath test after four weeks of drug withdrawal to compare the eradication rate and the adverse reaction rate.Results The eradication rate of group RBCA is 87.13%and the adverse reaction rate is 12.87%.The eradication rate of group EBCA is 85.58%and the adverse reaction rate is 19.23%.The difference between two groups was not statistically significant.Conclusion The efficacy and security of rabeprazole and esomeprazole are not different for HP-positive patients in Liaoning province.

关 键 词：雷贝拉唑 艾司奥美拉唑 根除率 安全性 

分 类 号：R573[医药卫生—消化系统]